VYNE Therapeutics (VYNE) Enterprise Value (2016 - 2025)
VYNE Therapeutics' Enterprise Value history spans 10 years, with the latest figure at -$29.0 million for Q4 2025.
- For Q4 2025, Enterprise Value rose 52.84% year-over-year to -$29.0 million; the TTM value through Dec 2025 reached -$29.0 million, up 52.84%, while the annual FY2025 figure was -$29.0 million, 52.84% up from the prior year.
- Enterprise Value reached -$29.0 million in Q4 2025 per VYNE's latest filing, up from -$39.6 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of $144000.0 in Q4 2022 to a low of -$119.5 million in Q1 2021.
- Average Enterprise Value over 5 years is -$50.7 million, with a median of -$50.3 million recorded in 2025.
- Peak YoY movement for Enterprise Value: skyrocketed 123.8% in 2022, then tumbled 64859.03% in 2023.
- A 5-year view of Enterprise Value shows it stood at -$605000.0 in 2021, then surged by 123.8% to $144000.0 in 2022, then crashed by 64859.03% to -$93.3 million in 2023, then skyrocketed by 34.03% to -$61.5 million in 2024, then skyrocketed by 52.84% to -$29.0 million in 2025.
- Per Business Quant, the three most recent readings for VYNE's Enterprise Value are -$29.0 million (Q4 2025), -$39.6 million (Q2 2025), and -$50.3 million (Q1 2025).